None of the 29 investors followed here reported a position in FNCHQ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a FNCHQ trade in the reports read so far (1,238 of 1,240; the rest are being read now).
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for FNCHQ.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.9 | -3.6 | -27.2 | -25.0 | 3.0 | 35.6 | -1.0 | 2.0 | 1.5 | 0.0 | −23.3% | ||
| 2025 | -0.4 | 40.3 | -9.1 | -12.9 | 8.0 | -2.2 | -8.9 | 8.1 | -5.5 | 9.2 | 0.7 | -0.1 | +19.4% |
| 2024 | -23.8 | -1.8 | -3.7 | -13.8 | -56.8 | 41.7 | 21.9 | 667.1 | -6.5 | 0.2 | 0.0 | -5.8 | +213.0% |
| 2023 | 4.2 | -17.2 | -5.1 | 2.6 | -30.6 | 1.5 | -10.2 | -15.7 | -19.8 | -25.1 | 8.0 | -13.8 | −74.9% |
| 2022 | -14.9 | -1.3 | -39.9 | -49.7 | -6.3 | 19.8 | -31.3 | 10.8 | -22.7 | -22.2 | -24.6 | -51.0 | −95.2% |
| 2021 | -13.3 | 4.2 | -3.6 | -6.4 | 7.4 | -8.1 | 3.1 | 24.0 | -40.0 | −38.3% |
No analyst coverage for this instrument.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on September 3, 2026.
No recent headlines.